source
- Merck teams with Isomorphic Labs to discover new oncology small-molecule candidatesMerck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
- Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese dataErasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…